Albert Lowe
Stock Analyst at Craig-Hallum
(2.77)
# 1,795
Out of 4,902 analysts
9
Total ratings
66.67%
Success rate
17.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiates: Buy | $50 | $22.60 | +121.24% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.87 | +360.03% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $1.17 | +415.02% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $3.72 | +276.34% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $2.84 | +287.32% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $4.45 | +79.78% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $0.99 | +304.04% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.33 | +351.13% | 1 | May 13, 2024 |
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $22.60
Upside: +121.24%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.87
Upside: +360.03%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $1.17
Upside: +415.02%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $3.72
Upside: +276.34%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $2.84
Upside: +287.32%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $4.45
Upside: +79.78%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $0.99
Upside: +304.04%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.33
Upside: +351.13%